CCTG MAC.20 Randomized Phase III Trial open to accrual

Sunday, October 1, 2017

We are please to announce that the MAC.20 trial is open to Canadian registrations and randomizations. CCTG MAC.20 / A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss In Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer (BWEL Study).

BWEL (Alliance: A011401) (CCTG: MAC.20) is the first study to test whether losing weight through reducing calories and exercising can lower the risk of breast cancer recurrence. This study will evaluate the role of weight loss in overweight (BMI ≥ 27) women with early breast cancer. Participants will have been diagnosed with invasive breast cancer within the past 12 months and completed all their chemotherapy, radiation and surgery before starting the study.

Please use the link below to view the memo, posted to the MAC.20 website, which contains more detail. Open to Canadian Accrual - 2017 September 20
https://www.ctg.queensu.ca/docs/trials/breast/mac20/status-updates/MAC20_Memo_Open_to_CDN_Accrual_2017SEP20.pdf